{
  "$schema": "folio-library-document/v1",
  "id": "10665-385346",
  "title": "Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran",
  "variant": "pdf",
  "pages": 12,
  "tocSource": "none",
  "tocMethod": null,
  "toc": [],
  "sections": [
    {
      "id": "page-001",
      "number": null,
      "title": "Page 1",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 1,
      "labelStart": null,
      "labelEnd": null,
      "words": 764,
      "summary": {
        "text": "Opening page of a 2019 Eastern Mediterranean Health Journal article on the cost-effectiveness of introducing the 13-valent pneumococcal conjugate vaccine (PCV-13) for children under 5 in the Islamic Republic of Iran, with authors and affiliations. The abstract describes use of the TRIVAC decision support model to estimate costs and disability-adjusted life years averted for pneumonia, meningitis, otitis media and other pneumococcal disease. The introduction notes that vaccinating young children also reduces disease indirectly by cutting nasopharyngeal carriage.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal conjugate",
          "heading": false
        },
        {
          "term": "invasive pneumococcal",
          "heading": false
        },
        {
          "term": "pneumococcal diseases",
          "heading": false
        },
        {
          "term": "streptococcus pneumoniae",
          "heading": false
        },
        {
          "term": "islamic republic",
          "heading": false
        },
        {
          "term": "introducing pcv",
          "heading": false
        },
        {
          "term": "iran university",
          "heading": false
        },
        {
          "term": "conjugate vaccines",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran Khadijeh Ezoji’,7, Mohsen Yaghoubi?, Marzieh Nojomi*, Sussan Mahmoody*, Seyed Mohsen Zahraie’, Maziar Moradi-Lakeh*, Sedigheh R. Tabatabaei® and Abdollah Karimi® ‘Social Determinants of Health Research Center, Health Research Institute, Babol",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-001"
      ]
    },
    {
      "id": "page-002",
      "number": null,
      "title": "Page 2",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": null,
      "labelEnd": null,
      "words": 866,
      "summary": {
        "text": "Explains that PCV-10 and PCV-13 are used in over 100 countries and that pneumococcal vaccine is not in Iran's schedule, although acute respiratory infection was the fourth leading cause of under-5 deaths in 2013. It describes the TRIVAC model, an Excel-based static cohort model developed by LSHTM with PAHO, ProVac and WHO, and the disease states considered. It then outlines the sources used for disease burden and vaccine efficacy inputs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal sequelae",
          "heading": false
        },
        {
          "term": "pneumococcal pneumonia",
          "heading": false
        },
        {
          "term": "pneumococcal meningitis",
          "heading": false
        },
        {
          "term": "acute otitis",
          "heading": false
        },
        {
          "term": "otitis media",
          "heading": false
        },
        {
          "term": "major sequelae",
          "heading": false
        },
        {
          "term": "vaccine efficacy",
          "heading": false
        },
        {
          "term": "non meningitis",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Afterrunning several clinical trials in different regions of the world, PCV-10 and PCV-13 have been introduced in the national vaccination programmes of more than 100 countries, including many low- and middle-income developing countries. These vaccines have been found to be cost-effective, especially in developing countries with limited health care resources (3,8,9), and",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-002"
      ]
    },
    {
      "id": "page-003",
      "number": null,
      "title": "Page 3",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 3,
      "labelStart": null,
      "labelEnd": null,
      "words": 489,
      "summary": {
        "text": "Describes the assumption that 70% of pneumococcal disease is covered by vaccine serotypes and how programme costs were estimated, using a vaccine price of US$ 20 per dose plus system costs. A table gives the estimated burden inputs, including incidence, case fatality, sequelae, disability weights and age distribution, with high and low scenarios.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal npnm",
          "heading": false
        },
        {
          "term": "pneumococcal pneumonia",
          "heading": false
        },
        {
          "term": "pneumococcal meningitis",
          "heading": false
        },
        {
          "term": "hortal",
          "heading": false
        },
        {
          "term": "gbd disease",
          "heading": false
        },
        {
          "term": "major sequelae",
          "heading": false
        },
        {
          "term": "acute otitis",
          "heading": false
        },
        {
          "term": "otitis media",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Serotype coverage Based on a systematic evaluation of global serotype cov- erage, we assumed that 70% of pneumococcal acute oti- tis media, pneumonia, meningitis, and non-pneumonia, non-meningitis infection were covered by the vaccine in the Islamic Republic of Iran (25,26). Cost estimation Vaccination programme costs We used WHO guidelines to calculate the costs of",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-003"
      ]
    },
    {
      "id": "page-004",
      "number": null,
      "title": "Page 4",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": null,
      "labelEnd": null,
      "words": 381,
      "summary": {
        "text": "Presents tables of the vaccine coverage inputs, based on DTP coverage by age in 2014, and the vaccine efficacy, serotype coverage and other assumptions used in the TRIVAC model for PCV-13.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pcv pneumococcal",
          "heading": false
        },
        {
          "term": "mohme",
          "heading": false
        },
        {
          "term": "trivac assumption",
          "heading": false
        },
        {
          "term": "pneumococcal conjugate",
          "heading": false
        },
        {
          "term": "pcv doses",
          "heading": false
        },
        {
          "term": "pneumococcal pneumonia",
          "heading": false
        },
        {
          "term": "trivac model",
          "heading": false
        },
        {
          "term": "conjugate vaccine",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Table 2 Estimated vaccine coverage in the Islamic Republic of Iran used for the TRIVAC model Scenario Variable Estimate (%) Source/s High Low Coverage of DTP1 by age in 2014 (proxy for PCV doses given with DTP1) 3m 97.2 NA NA MoHME 6m 98.5 NA NA MoHME om 98.9 NA NA MoHME 2m 99.3 NA NA MoHME 24m 100.0 NA NA MoHME Coverage of DTP2 by age in 2014 (proxy for PCV doses given",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-004"
      ]
    },
    {
      "id": "page-005",
      "number": null,
      "title": "Page 5",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": null,
      "labelEnd": null,
      "words": 668,
      "summary": {
        "text": "Presents a table of programme cost inputs, including projected vaccine prices falling from US$ 20 in 2014, handling, wastage and system costs. It describes assumptions on hospitalization and outpatient care and the split between public and private providers. Costs were converted at 35 000 rials per US dollar, and the sensitivity analysis approach is introduced.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "trivac assumption",
          "heading": false
        },
        {
          "term": "inpatient admission",
          "heading": false
        },
        {
          "term": "outpatient costs",
          "heading": false
        },
        {
          "term": "household costs",
          "heading": false
        },
        {
          "term": "average inpatient",
          "heading": false
        },
        {
          "term": "outpatient visit",
          "heading": false
        },
        {
          "term": "iranian ministry",
          "heading": false
        },
        {
          "term": "government costs",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Table 4 Data used for variables in the TRIVAC model to estimate programme costs of pneumococcal conjugate vaccine-13 Variable Estimate Scenario Source/s Projected vaccine price per dose (US$) 2014 20.00 2015 18.00 2016 16.20 2017 14.58 2018 13.12 2019 1.81 2020 10.63 2021 9.57 2022 8.61 2023 7-75 Other vaccine dose costs International handling (% of vaccine price) 3.0",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-005"
      ]
    },
    {
      "id": "page-006",
      "number": null,
      "title": "Page 6",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": null,
      "labelEnd": null,
      "words": 390,
      "summary": {
        "text": "Presents a table of health service use and cost inputs per outpatient visit and inpatient admission, from government and household perspectives. Results begin, reporting that PCV-13 would avert about 10 000 deaths over 2014–2023 and be highly cost-effective at about US$ 1890 and US$ 1538 per DALY averted for government and society.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal npnm",
          "heading": false
        },
        {
          "term": "pneumococcal meningitis",
          "heading": false
        },
        {
          "term": "pneumococcal pneumonia",
          "heading": false
        },
        {
          "term": "meningitis sequelae",
          "heading": false
        },
        {
          "term": "trivac assumption",
          "heading": false
        },
        {
          "term": "major sequelae",
          "heading": false
        },
        {
          "term": "mohme",
          "heading": false
        },
        {
          "term": "sequelae year",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Table 5 Data used for variables in the TRIVAC model to estimate health service utilization and costs (all costs are for 2014) Scenario Variable Estimate Source/s High Low Outpatient visits Outpatient visits per disease episode All-cause acute otitis media 1 1 0.7 MoHME Pneumococcal pneumonia 0.47 0.6 0.2 MoHME Pneumococcal meningitis 0.05, 0.08 0.02 MoHME Pneumococcal",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-006"
      ]
    },
    {
      "id": "page-007",
      "number": null,
      "title": "Page 7",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": null,
      "labelEnd": null,
      "words": 488,
      "summary": {
        "text": "Gives a table of pneumococcal cases, visits, admissions, deaths and DALYs with and without PCV-13 for ten cohorts. It describes the sensitivity analysis of 19 scenarios, including the most and least favourable, and begins comparing results with WHO cost-effectiveness benchmarks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal npnm",
          "heading": false
        },
        {
          "term": "pneumococcal pneumonia",
          "heading": false
        },
        {
          "term": "pneumococcal meningitis",
          "heading": false
        },
        {
          "term": "pneumococcal disease",
          "heading": false
        },
        {
          "term": "discounted cost",
          "heading": false
        },
        {
          "term": "vaccine price",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "vaccine efficacy",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Table 6 Estimated health burden of pneumococcal diseases with and without PCV-13, and discounted health benefitsa of PCV-13 for 10 cohorts vaccinated over the period 2014-2023 Variable Cases of pneumococcal disease in children < 5 years (no.) Total cases All-cause acute otitis media Pneumococcal pneumonia Pneumococcal meningitis Pneumococcal NPNM Outpatient visits for",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-007"
      ]
    },
    {
      "id": "page-008",
      "number": null,
      "title": "Page 8",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": null,
      "labelEnd": null,
      "words": 638,
      "summary": {
        "text": "Discusses the results: vaccination could prevent over 4.5 million cases and 38% of pneumococcal deaths, and avert about a third of the societal economic burden over 2014–2023. It compares findings with cost-effectiveness studies from Egypt, Peru and Croatia. It notes limitations, including limited private-sector data, followed by a cost table.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal npnm",
          "heading": false
        },
        {
          "term": "pneumococcal pneumonia",
          "heading": false
        },
        {
          "term": "pneumococcal meningitis",
          "heading": false
        },
        {
          "term": "pneumococcal diseases",
          "heading": false
        },
        {
          "term": "pcv",
          "heading": false
        },
        {
          "term": "estimated costs",
          "heading": false
        },
        {
          "term": "inpatient admissions",
          "heading": false
        },
        {
          "term": "visit costs",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 DALY averted of less than three times the gross domestic product per capita should be considered cost-effective (30). We estimated that vaccination could prevent more than 4.5 million cases of pneumococcal-associated disease over the period 2014-2023. A national immunization programme with PCV-13 was estimated to prevent 38% of all deaths from pneumococcal diseases. The",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-008"
      ]
    },
    {
      "id": "page-009",
      "number": null,
      "title": "Page 9",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": null,
      "labelEnd": null,
      "words": 386,
      "summary": {
        "text": "Presents the table of discounted cost-effectiveness of PCV-13 for government and society against GDP-based thresholds and a figure of the sensitivity analysis scenarios. It concludes that PCV-13 would be a high-impact intervention for Iran and that evidence should guide new vaccine introduction.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gdp",
          "heading": false
        },
        {
          "term": "vaccine price",
          "heading": false
        },
        {
          "term": "gross domestic",
          "heading": false
        },
        {
          "term": "islamic republic",
          "heading": false
        },
        {
          "term": "pneumococcal disease",
          "heading": false
        },
        {
          "term": "case fatality",
          "heading": false
        },
        {
          "term": "pcv",
          "heading": false
        },
        {
          "term": "averted",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Table 8 Discounted cost-effectiveness* of PCV-13 (10 cohorts vaccinated over the period 2014-2023) compared with no vaccination for the government and society Government Society Net cost of PCV-13 introduction (million US$) Cost of vaccine introduction Health service costs avoided DALYs averted (000s) Years lived with disability averted Years of life lost averted USs per",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-009",
        "library/10665-385346/blocks/figure-vfig-p009"
      ]
    },
    {
      "id": "page-010",
      "number": null,
      "title": "Page 10",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 10,
      "labelStart": null,
      "labelEnd": null,
      "words": 638,
      "summary": {
        "text": "A page from a 2019 Eastern Mediterranean Health Journal article on introducing the 13-valent pneumococcal conjugate vaccine for children under five in the Islamic Republic of Iran, closing the English text with acknowledgements, funding from the ProVac International Working Group and a statement of no competing interests. It then gives French and Arabic abstracts: the TRIVAC model, using local cost data, estimated about 18.7 million pneumococcal cases over 2014–2023 without vaccination, of which the vaccine would prevent about 4.9 million, along with 105 802 hospitalizations and 9997 deaths. The authors judge the vaccine cost-effective against WHO thresholds; the French and Arabic OCR is noticeably garbled, especially accents and Arabic numerals, and the Arabic abstract is cut off.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "الالتهاب الرئوي",
          "heading": false
        },
        {
          "term": "islamique iran",
          "heading": false
        },
        {
          "term": "infection pneumocoque",
          "heading": false
        },
        {
          "term": "الرئوية",
          "heading": false
        },
        {
          "term": "république islamique",
          "heading": false
        },
        {
          "term": "otite moyenne",
          "heading": false
        },
        {
          "term": "الوسطى الحاد",
          "heading": false
        },
        {
          "term": "تكلفة إدراج",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Acknowledgments We are grateful to the Iranian Ministry of Health and Medical Education, especially the Center for Communicable Disease Control, and the WHO country office in the Islamic Republic of Iran. We thank all advisers and colleagues, espe- cially Gabriela Felix, for their technical support. Funding: This work was supported by the ProVac International Working",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-010"
      ]
    },
    {
      "id": "page-011",
      "number": null,
      "title": "Page 11",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": null,
      "labelEnd": null,
      "words": 788,
      "summary": {
        "text": "Contains the end of the garbled Arabic abstract, which is unreadable in the extracted text, followed by the start of the reference list citing global pneumococcal burden estimates, Cochrane and cost-effectiveness studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal conjugate",
          "heading": false
        },
        {
          "term": "valent pneumococcal",
          "heading": false
        },
        {
          "term": "conjugate vaccine",
          "heading": false
        },
        {
          "term": "conjugate vaccination",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "bmc infect",
          "heading": false
        },
        {
          "term": "cost-effectiveness analysis",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 Jot OF Lt ys PCV V9 CU plas oly, UBL plaszel O99 oye CV TT LY VE ye) Sl ee he V9 JE (FAV AG bbl bg EVAN £04 cLL) dea IN OSV lel V4 AEF oS LID 48 Sly Ul Sp DE EV AE RLS O50 Js BES ML SU spe ee Byes CLEVE T LES lel sls SS OLS ye dell oe ssl TOTS bball Bb Die AA AV. 3 patie J po SVL oye VP ONY Cad Sad egal as Li. By DL VATA bye piteell Lis ye YAV qos pel gee ope SEE Se IST",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-011"
      ]
    },
    {
      "id": "page-012",
      "number": null,
      "title": "Page 12",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": null,
      "labelEnd": null,
      "words": 325,
      "summary": {
        "text": "The end of the reference list for the PCV-13 cost-effectiveness article, citing studies on vaccine efficacy, serotypes, WHO guidance on cost-effectiveness analysis and a Croatian economic evaluation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "serotypes",
          "heading": false
        },
        {
          "term": "conjugate",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "vaccine",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "icd",
          "heading": false
        }
      ],
      "extract": "Research article EMH] - Vol. 25 No. 10 - 2019 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. Griffiths UK. Haemophilus influenzae type b vaccine in low- and middle-income countries: impact, costs and incremen- tal cost-utility [PhD thesis].London: London School of Hygiene and Tropical Medicine; 2012. doi: https://doi.org/10.17037/ PUBS.02869500 Hortal M, Estevan M, Iraola I, De Mucio B. A population-based assessment of",
      "extractCut": true,
      "blocks": [
        "library/10665-385346/blocks/prose-page-012"
      ]
    }
  ],
  "checks": {},
  "withheld": false,
  "keywords": [
    {
      "term": "pcv pneumococcal",
      "heading": false
    },
    {
      "term": "pneumococcal vaccine",
      "heading": false
    },
    {
      "term": "pneumococcal pneumonia",
      "heading": false
    },
    {
      "term": "pneumococcal conjugate",
      "heading": false
    },
    {
      "term": "pneumococcal npnm",
      "heading": false
    },
    {
      "term": "pneumococcal meningitis",
      "heading": false
    },
    {
      "term": "pneumococcal sequelae",
      "heading": false
    },
    {
      "term": "pneumococcal disease",
      "heading": false
    },
    {
      "term": "invasive pneumococcal",
      "heading": false
    },
    {
      "term": "valent pneumococcal",
      "heading": false
    },
    {
      "term": "pcv averted",
      "heading": false
    },
    {
      "term": "introducing pcv",
      "heading": false
    }
  ],
  "images": [
    {
      "id": "vfig-p009",
      "file": "figures/vfig-p009.webp",
      "page": 9,
      "shows": [
        "Table 8",
        "Figure 1"
      ],
      "narratives": {
        "en": "The top is the lower part of a table comparing government and society perspectives for PCV-13 introduction: net cost US$ 573.31 million vs 466.53 million, DALYs averted 303.34 thousand in both, US$ per DALY averted 1 890 vs 1 538, against thresholds of 1 × GDP per capita (4 526) and 3 × GDP per capita (13 578). Below, Figure 1 is a horizontal bar chart titled “Sensitivity Analysis” with paired dark-blue and light-blue bars for about 20 scenarios, from “Least favourable” (longest bars) through “Base case scenario” to “Most favourable”, marked with a red arrow labelled “Cost saving”. Dashed vertical lines mark 1*GDP and 3*GDP; all bars stay left of the 1*GDP line, and no axis values or legend are visible.",
        "ar": "يُظهر الجزء العلوي الجزء الأخير من جدول يقارن بين منظور الحكومة ومنظور المجتمع لإدخال اللقاح PCV-13: صافي التكلفة 573.31 مليون دولار أمريكي مقابل 466.53 مليون، وسنوات العمر المصححة باحتساب مدد العجز (DALYs) المتجنبة 303.34 ألف في الحالتين، والتكلفة لكل سنة DALY متجنبة 1 890 مقابل 1 538 دولارًا أمريكيًا، مقارنة بالعتبتين 1 × الناتج المحلي الإجمالي للفرد (4 526) و3 × الناتج المحلي الإجمالي للفرد (13 578). وفي الأسفل، الشكل 1 مخطط أعمدة أفقية بعنوان «Sensitivity Analysis» (تحليل الحساسية) يضم أعمدة مزدوجة بالأزرق الداكن والأزرق الفاتح لنحو 20 سيناريو، من «الأقل ملاءمة» (أطول الأعمدة) مرورًا بـ«سيناريو الحالة الأساسية» إلى «الأكثر ملاءمة»، مع سهم أحمر يحمل عبارة «توفير التكاليف». وتحدد خطوط رأسية متقطعة مستويي 1*GDP و3*GDP؛ وتبقى جميع الأعمدة على يسار خط 1*GDP، ولا تظهر قيم على المحور ولا مفتاح للرموز.",
        "zh": "上部为一张表格的下半部分，比较引入PCV-13的政府视角与社会视角：净成本分别为5.7331亿美元和4.6653亿美元；避免的伤残调整生命年（DALY）均为303.34千；每避免一个DALY的成本分别为1 890美元和1 538美元；对照阈值为人均国内生产总值的1倍（4 526）和3倍（13 578）。下方图1为题为“Sensitivity Analysis”（敏感性分析）的水平条形图，约20种情景各有一对深蓝色和浅蓝色条形，从“最不利”（条形最长）经“基准情景”到“最有利”，后者标有红色箭头和“节约成本”字样。虚线竖线标示1*GDP和3*GDP；所有条形均位于1*GDP线左侧，图中未显示坐标轴数值或图例。",
        "es": "En la parte superior aparece la parte final de un cuadro que compara las perspectivas del gobierno y de la sociedad respecto a la introducción de la PCV-13: costo neto de US$ 573,31 millones frente a 466,53 millones, AVAD evitados 303,34 mil en ambos casos, y US$ por AVAD evitado 1 890 frente a 1 538, en comparación con los umbrales de 1 × PIB per cápita (4 526) y 3 × PIB per cápita (13 578). Debajo, la figura 1 es un gráfico de barras horizontales titulado «Sensitivity Analysis» (análisis de sensibilidad) con pares de barras azul oscuro y azul claro para unos 20 escenarios, desde «Menos favorable» (barras más largas), pasando por «Escenario de base», hasta «Más favorable», señalado con una flecha roja con la leyenda «Ahorro de costos». Líneas verticales discontinuas marcan 1*PIB y 3*PIB; todas las barras quedan a la izquierda de la línea de 1*PIB, y no se ven valores en el eje ni leyenda.",
        "fr": "En haut figure la fin d’un tableau comparant les perspectives des pouvoirs publics et de la société pour l’introduction du PCV-13 : coût net de 573,31 millions US$ contre 466,53 millions, DALY évités 303,34 milliers dans les deux cas, et US$ par DALY évité 1 890 contre 1 538, à comparer aux seuils de 1 × PIB par habitant (4 526) et 3 × PIB par habitant (13 578). En dessous, la figure 1 est un graphique à barres horizontales intitulé « Sensitivity Analysis » (analyse de sensibilité), avec des paires de barres bleu foncé et bleu clair pour une vingtaine de scénarios, du « moins favorable » (barres les plus longues) au « plus favorable », en passant par le « scénario de référence » ; ce dernier extrême est signalé par une flèche rouge portant la mention « Économies ». Des lignes verticales en pointillé marquent 1*PIB et 3*PIB ; toutes les barres restent à gauche de la ligne 1*PIB, et aucune valeur d’axe ni légende n’est visible.",
        "ru": "В верхней части показан конец таблицы, сравнивающей позиции государства и общества в отношении внедрения PCV-13: чистые затраты 573,31 млн долл. США против 466,53 млн, предотвращённые DALY — 303,34 тыс. в обоих случаях, стоимость одного предотвращённого DALY — 1 890 против 1 538 долл. США, при пороговых значениях 1 × ВВП на душу населения (4 526) и 3 × ВВП на душу населения (13 578). Ниже рисунок 1 — горизонтальная столбчатая диаграмма «Sensitivity Analysis» (анализ чувствительности) с парами тёмно-синих и светло-синих столбцов примерно для 20 сценариев: от «наименее благоприятного» (самые длинные столбцы) через «базовый сценарий» до «наиболее благоприятного», отмеченного красной стрелкой с подписью «Экономия затрат». Пунктирные вертикальные линии обозначают 1*ВВП и 3*ВВП; все столбцы находятся левее линии 1*ВВП, значения на оси и легенда не видны."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "not-extracted",
      "note": "split one section per page; no contents was trusted"
    },
    {
      "kind": "sections",
      "state": "partial",
      "count": 12,
      "note": "one per page, not by heading"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 1
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p11); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "none"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 12,
      "note": "12 of 12 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-385346"
  }
}
